ROKIT Healthcare presented one- to two-year follow-up results at EWMA 2026 showing AI-driven, autologous fat-derived bioprinted tissue achieved functional, sensory, and aesthetic recovery after skin cancer reconstruction.
Key Takeaways
- ROKIT Healthcare reported one- to two-year follow-up for patients treated with autologous
- Company-reported outcomes included functional recovery
- ROKIT demonstrated its end-to-end platform live at EWMA 2026 and held meetings with hospitals